



MAGNASENSE FILES A PATENT APPLICATION

Magnasense AB, a leading innovator in diagnostic technologies, today announces the filing of a patent application covering an advanced detection system designed to improve the sensitivity and accuracy of magnetic test strips using superparamagnetic nanoparticles.

The patent-pending system introduces a novel method for detecting superparamagnetic nanoparticles in magnetic test strips. It incorporates a magnetic field generator activated by an excitation signal, paired with a magnetic field sensor that measures shifts in magnetic field strength. When specific biomarkers are present in a sample, the sensor detects these changes, allowing for accurate detection and measurement of target analytes.

"Our technology marks a significant advancement in point-of-care diagnostics," said Marco Witteveen, CEO of Magnasense. "The enhanced sensitivity and precision of our system will enable earlier, more reliable detection of biomarkers across a wide range of conditions and sample types. This innovation has the potential to reduce cost per test and redefine how diagnostic testing is conducted."

The patent-pending system introduces a novel method for detecting superparamagnetic nanoparticles in magnetic test strips. It incorporates a magnetic field generator activated by an excitation signal, paired with a magnetic field sensor that measures shifts in magnetic field strength. When specific biomarkers are present in a sample, the sensor detects these changes, allowing for accurate detection and measurement of target analytes. The application filing number is 63/693,525.

Ideally suited for point-of-care applications, the technology facilitates rapid, dependable diagnostics without the need for complex lab infrastructure. Its versatility allows it to be applied across various disease states, providing healthcare professionals with the tools to make quicker, better-informed decisions. This breakthrough promises to have wide-reaching applications in healthcare, benefiting both medical practitioners and patients through improved diagnostic accuracy.

For additional information, please contact:

Marco Witteveen, CEO, Magnasense AB

Email: ir@magnasense.com

The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

**About Magnasense AB**

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.